SARS-CoV-2 infections in patients enrolled on the Children's Oncology Group standard-risk B-cell acute lymphoblastic leukemia trial, AALL1731.

Authors :: Elgarten CW
Kairalla JA
Thompson JC
Miller TP
Wang C
Conway S
Loh ML
Raetz EA
Gupta S
Rau RE
Angiolillo A
Rabin KR
Alexander S
Source :: EJHaem [EJHaem] 2023 May 10; Vol. 4 (3), pp. 745-750. Date of Electronic Publication: 2023 May 10 (Print Publication: 2023).
Publication Year :: 2023
Abstract: Hematologic malignancy is a risk factor for severe coronavirus disease 2019 (COVID-19) in adults; however, data specific to children with leukemia are limited. High-quality infectious adverse event data from the ongoing Children's Oncology Group (COG) standard-risk B acute lymphoblastic leukemia/lymphoma (ALL/LLy) trial, AALL1731, were analyzed to provide a disease-specific estimate of SARS-CoV-2 infection outcomes in pediatric ALL. Of 253 patients with reported infections, the majority (77.1%) were asymptomatic or mildly symptomatic (CTCAE grade 1/2) and there was a single COVID-19-related death. These data suggest SARS-CoV-2 infection does not confer substantial morbidity among young patients with B-lymphoblastic leukemia/lymphoma (B-ALL/LLy).<br />Competing Interests: The authors declare they have no conflicts of interest.<br /> (© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)

Full Text Access

Tools